# Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

> **NCT07744256** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- Relapsed/Refractory SCLC
- Extensive-stage SCLC

## Interventions

- **BIOLOGICAL:** EB-DART-NK01
- **DRUG:** Lymphodepleting chemotherapy

## Key facts

- **NCT ID:** NCT07744256
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-02-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744256, "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07744256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*